Source: Recce Pharmaceuticals
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Recce Pharmaceuticals (ASX:RCE) has received a $6.75 million Research and Development (R&D) Tax Incentive rebate from the Australian Taxation Office for FY24.

This receipt was used to repay advances from Endpoints Capital reflecting R&D rebate credits for FY24.

The Company is developing a new class of Synthetic Anti-infectives and the injection of funds reflects R&D activities undertaken locally and overseas.

The Australian Government’s 43.5% Research & Development Tax Incentive rebate is intended to incentivise companies to develop new innovative solutions onshore.

“We are delighted to receive this substantial R&D Tax Incentive rebate, which underscores the Australian Government’s strong support for innovation in life sciences,” Recce CEO James Graham said.

“This funding strengthens our ability to drive forward our R&D initiatives both domestically and internationally, accelerating our mission
to develop cutting-edge anti-infective solutions.

“By leveraging this rebate, we continue to push the boundaries of synthetic anti-infective development, positioning Recce to deliver
meaningful advancements in infection treatment on a global scale.”

Recce last traded at 49.5cps.

RCE by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Bourse finishes week on a high as Wisetech pummeled | November 22, 2024

The ASX200 closed up 0.85% at 8,393 points. Economists increasingly expect interest rates in Australia won’t…
The Market Online Video

HotCopper Highlights: Your most watched stocks for Week 47, 2024

In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing,…
Nuclear explosion mushroom cloud concept

Week 47 Wrap: HotCopper users’ most watched; Brent lifts on Putin’s scary letter; RFK dents CSL

Welcome to the end of another week. Let's start with what HotCopper users have been watching…
Dale Gillham's photo, and wording 'Words from Wealth Within's Chief Analyst Dale Gillham.

Dale Gillham’s weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in th…